Russia sets new record for labour shortage despite high wages
As of the end of 2024, Russian companies faced a shortage of 2.6 million workers, a 17% increase compared to the previous year, setting a new record.
Source: The Moscow Times, citing a report by Russia's Higher School of Economics
Details: The most acute shortages are in manufacturing (391,000 workers), trade (347,000) and transport (219,000). Employers in these sectors are offering salaries above RUB 100,000 (approx. US$ 717), around one and a half times higher than the national average.
The study attributes the growing number of job openings in manual labour professions to a decline in migrant workers, the depreciation of the rouble, and the impact of a series of economic shocks.
The outlet notes that the deepening labour crisis is directly linked to the consequences of Russia's full-scale war against Ukraine.
In 2022, around 300,000 working-age men were mobilised. Meanwhile, between 650,000 and 1.1 million people left the country, protesting Kremlin policies and fleeing mobilisation. Further army recruitment has only worsened the labour shortage.
At the same time, sanctions have weakened the economy and triggered a sharp fall in the rouble. This, along with tighter migration laws, has led to a significant outflow of citizens from Central Asian countries.
Background: In the first quarter of 2025, domestic sales of Russian agricultural machinery dropped sharply.
Support Ukrainska Pravda on Patreon!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Stablecoin issuer Circle soars in public market debut
Shares of stablecoin issuer Circle soared in its NYSE debut today, a validation of crypto's newfound importance to the American financial system and a symptom of investors starved for new issuances during a long IPO drought. Trading in the stock was halting just seconds after it began after the stock, which had been sold last night to IPO investors for $31 a share, opened at $69 and soared to nearly $76. The $31 price was below where Circle was previously valued by private investors. In an interview off the NYSE trading floor with Semafor, CEO Jeremy Allaire said he worried that if the US doesn't create a trusted and useful digital dollar — something his company's main product, USD Coin, aims to be — it might lose the 'digital currency space race' to China, which has a formidable lead over the US with its digital yuan. 'The digital dollar should be the highest utility money in the world,' he said. 'We are believers in the strength and continued preeminence of the dollar in the global financial system, and in the internet financial system that's being built up.' It's the digital version of a broader debate about the future of the dollar, as the global economy fractures under trade and geopolitical tensions. It's also a politically expedient play for Allaire's company, which, as the Financial Times notes, is quite exposed to the whims of central banks. A rival stablecoin issuer, Tether, has also latched onto the US-China rivalry. Liz Hoffman: The House passed stablecoin legislation. What's your expectation for what happens in the Senate? Jeremy Allaire: The GENIUS Act had a bipartisan supermajority to get it to where it is, and we believe it's an excellent piece of legislation. This is part of an effort by policymakers and governments around the world to integrate stablecoins as an M1-like electronic money type in the financial system. It represents a tremendous opportunity to have more companies, more financial institutions, more technology firms, build on this breakthrough technology. Do you expect competition from the Trump family? Circle has always faced competition. The position we've been able to build as a licensed, regulated, global firm — we think those remain strengths, and we're very comfortable that we're going to continue to be the leader. Becoming a public company is significant in terms of enhancing trust, transparency, and accountability. Crypto is right on the cusp of going mainstream, but is still shot through with fraud and criminal-adjacent actors. Do you think you can fully drag it into the sunlight? We aren't focused on speculative trading or different types of digital assets. We're trying to improve the financial system by building a new, electronic form of the dollar, and ultimately other fiat electronic money, to make the global economic system more fair and integrated. We saw, in the birth and growth of the internet, a huge range of things that people thought were useful — some of which became fundamental to all of our lives and some of which don't exist anymore. Do you worry that if the US doesn't become the backbone of that global digital infrastructure that someone else, maybe the Chinese, will? I do. The digital dollar should be the highest utility money in the world. We're trying to cement in law a framework that assures that the United States … can win the digital- currency space race. We are believers in the strength and continued preeminence of the dollar in the global financial system, and in the internet financial system that's being built up. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Exclusive-Ukraine hits out at Europe's payout from frozen Russian cash
By Tom Balmforth and John O'Donnell KYIV/BRUSSELS (Reuters) -Ukraine's government has criticised a decision to take billions of euros of Russian wealth frozen in Europe and hand it to Western investors, warning that it weakened Europe's stand against Moscow. The criticism follows a move last month by Belgium's Euroclear to take 3 billion euros ($3.4 billion) of Russian investor cash held at the clearing firm to pay Westerners who lost out when Moscow seized their money held in Russia. Now Ukraine has warned that it sends a wrong signal and threatens to weaken Europe's hand when dealing with Russia, while it debates using the entire $300 billion of Russian wealth stranded in Europe to rebuild and defend the battered country. "If private investors are compensated before the victims of war, it won't be justice," said Iryna Mudra, a senior official in Ukrainian President Volodymyr Zelenskiy's office, in Kyiv's first public comments on the move. "It creates a perception of inconsistency, of Europe wavering in its resolve," Mudra, a deputy head of Ukraine's presidential administration, told Reuters. "International law requires that the aggressor is to make full reparation to the victim and not to investors who ... entered a high-risk jurisdiction," said Mudra, who is in charge of legal affairs in Zelenskiy's administration. The criticism comes at a critical time for the Western alliance backing Kyiv, with U.S. President Donald Trump's administration distancing itself from Europe and casting doubt over its commitment to Ukraine's defence and Russian sanctions. Mudra, one of a small circle of officials that set policy, also stressed the importance of maintaining control of the frozen Russian assets, which chiefly belong to its central bank with the majority held at Euroclear. The central bank assets were frozen at the outset of war in the single most powerful sanction directed at Russia over its full-scale invasion of Ukraine, a penalty that is deeply resented in Moscow. Euroclear in March gained clearance from Belgium, its principal legal authority, to make the payout, people familiar with the matter have told Reuters, after the European Union changed its sanctions regime last year to make this possible. A spokesperson for the Belgian government said: "This is not a Belgian decision but the application of a European regulation decided unanimously by the member states." Euroclear has emphasised that it only implements sanctions and does not take decisions about lifting them. 'MIND BOGGLING' Three Russian sources recently told Reuters that Russian President Vladimir Putin's conditions for ending the war include the resolution of the frozen assets issue. Ukraine, meanwhile, is campaigning fiercely against any return of the money to Moscow. Euroclear alone held 195 billion euros of cash in March - mainly Russian central bank funds, with some belonging to Russian investors. "If it is returned to Russia, it will be converted into tanks, missiles, drones, training of new troops," said Ukraine's Mudra. "The world ... must demonstrate that unlawful war brings irreversible financial consequences." Some see the frozen Russian wealth as a lifeline for Kyiv. In the past, the West has engineered loans and payments to Ukraine from the interest on the stranded Russian stockpile, which Putin denounced as theft. Ukrainian officials fear the Euroclear payout, even though it does not affect the central bank money, could undermine their efforts to secure an agreement on using the wider pool of Russian assets to help their country. Mykola Yurlov, an official at Ukraine's Ministry of Foreign Affairs, said the payout set a bad precedent, while Kira Rudik, a Ukrainian parliamentarian, was also critical. "Western companies were operating in Russia at their own risk. Why are these companies basically asking their societies to compensate for this risk?" Rudik told Reuters. "We need this money to rebuild and defend Ukraine." Last month's move also drew criticism abroad. "It is mind boggling that the priority is to reimburse corporate interests rather than spend the money defending Ukraine," said Jacob Kirkegaard, a sanctions expert with the Peterson Institute for International Economics, a Washington-based think tank. While the payout to investors left frozen Russian central bank reserves untouched, it made a dent in the stockpile of Russian wealth that gives the EU leverage over Moscow. More importantly for critics, it sets a worrying precedent. European Union leaders are expected to renew sanctions, including a freeze of Russian assets, at a summit meeting in June, although they could yet face an attempt by Hungary to derail those efforts. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Elastomeric Infusion Pumps Market Set to Reach Valuation of US$ 1,357.40 Million By 2033
Demand for elastomeric infusion pumps is accelerating on clinician convenience, home-care growth, sustainable materials innovation, and regulatory harmonization, while digital supply chains and service ecosystems sharpen competition, driving product customization and regional adoption momentum. Chicago, June 05, 2025 (GLOBE NEWSWIRE) -- The global elastomeric infusion pumps market was valued at US$ 741.56 million in 2024 and is expected to reach US$ 1,357.40 million by 2033, growing at a CAGR of 7.85% during the forecast period 2025–2033. Bedside nursing teams cite speed and simplicity as decisive factors when selecting analgesic and antibiotic delivery devices. Unlike electronic programmable options requiring multistep calibration, disposable balloon pumps arrive pre-filled and ready within seconds, freeing clinicians during peak rounds. In the United States alone, more than forty-two thousand postoperative pain-management cases in 2023 relied on such devices, according to Premier's hospital supply database. European day-case surgery centers report a mean five-minute reduction in discharge preparation time per patient. These operational savings, multiplied across high-throughput facilities, form a powerful demand engine within the elastomeric infusion pumps market, particularly as staffing shortages intensify worldwide. Request Sample Pages: Patient autonomy is an equally potent catalyst. A British Pain Society audit involving 300 participants recorded 261 individuals walking unaided to bathrooms while on elastomeric devices, whereas only 129 managed the same action when tethered to electronic pumps. This freedom translated into six fewer breakthrough-analgesia doses per case at Seoul's Samsung Medical Center. Under value-based reimbursement, administrators monitoring readmission penalties treat mobility as a fidelity metric, thereby amplifying interest in the elastomeric infusion pumps market. Rural outreach programs in Canada now bundle balloon pumps with telehealth follow-ups, proving cost-effective despite harsh winter logistics. Expanded drug-specific home-use labeling expected in 2024 will further accelerate the global elastomeric infusion pumps market. Key Findings in the Elastomeric Infusion Pumps Market Market Forecast (2033) US$ 1,357.40 million CAGR 7.85% Largest Region (2024) North America (38.24%) By Product Type Continuous Rate Elastomeric Pumps (65%) By Application Pain Management (40%) By End Users Hospitals (44%) By Distribution Channel Direct Sales (B2B) (40%) Top Drivers Growing preference for home-based chemotherapy and pain management solutions Rising geriatric population requiring continuous medication delivery for chronic conditions Cost-effectiveness compared to electronic pumps reducing healthcare facility expenses Top Trends Integration of antimicrobial coating technologies in pump manufacturing for safety Shift towards larger reservoir capacities accommodating extended therapy duration requirements Adoption of multi-rate flow controllers enabling flexible dosing without replacement Top Challenges Limited flow rate adjustability compared to programmable electronic infusion pumps Temperature sensitivity affecting drug stability during prolonged ambulatory use periods Disposal concerns regarding non-recyclable elastomeric materials impacting environmental sustainability goals Material Science Innovations Elevating Precision And Extending Drug Stability Durations Recent advances in thermoplastic elastomers and multilayer silicone composites are pushing pressure consistency to unprecedented tolerances. In 2024, Japanese supplier Zeon Medical commercialized a proprietary styrene-isoprene block copolymer that keeps pressure deviation within ±3 mm Hg over a twelve-hour infusion. During validation at the Cleveland Clinic, the material delivered vancomycin with less than two milligrams cumulative variance, outperforming legacy latex balloons by a factor of four. Low residual drug volumes mean antimicrobial-stewardship committees can tighten dosing protocols, reducing the need for top-up syringes. Such precision is fast becoming a differentiator within the elastomeric infusion pumps market, especially as oncology pharmacies formulate high-cost monoclonal cocktails that cannot tolerate wastage in today's reimbursement-constrained hospital environment. Extended stability is the second material frontier. New ethylene-vinyl-acetate liners infused with UV blockers preserve light-sensitive chemotherapy compounds for up to twenty-four hours at ambient temperatures, according to a 2024 multicenter study led by France's Institut Curie. Pharmacies report that longer beyond-use dating halves the number of evening batch preparations, releasing staff for clinical-validation tasks. Importantly, the environmental profile is improving as well. Baxter's latest pump range now incorporates biobased thermoplastics certified under the USDA BioPreferred Program, cutting fossil-resin consumption by ten metric tons per million units. As hospital sustainability dashboards gain executive visibility, these advances strengthen vendor positioning within the elastomeric infusion pumps market. Regulatory Harmonization Streamlining Approvals While Raising Postmarket Surveillance Expectations Globally The regulatory scene for disposable infusion devices has shifted since the U.S. FDA reclassified elastomeric pumps to Class II with special controls in late 2023. The update introduced clearer consensus standards—ISO 28620:2021 for volumetric accuracy and ISO 80369-7 for connector integrity—allowing manufacturers to pursue the 510(k) pathway without separate clinical trials for every flow-rate variant. Health Canada followed suit within six months, referencing identical benchmarks. Harmonization compresses certification timelines; consultancy Emergo notes dossier review periods falling from twenty-three to eleven weeks. For hospital buyers, faster iteration loops mean field feedback—such as flow deceleration during altitude changes—can be rectified within the same fiscal year across the elastomeric infusion pumps market. However, streamlined entry is counter-balanced by stricter postmarket vigilance across the elastomeric infusion pumps market. Under Europe's Medical Device Regulation, manufacturers must submit Periodic Safety Update Reports summarizing complaint trends, adverse events, and corrective actions each calendar year. The first wave of submissions in 2024 revealed 94 micro-leak events at luer joints out of 282 adverse device incidents logged on EUDAMED, prompting regulators to recommend crimp-torque audits during production. Simultaneously, China's National Medical Products Administration expanded its unique-device-identification pilot to cover elastomeric pumps distributed in Guangdong Province, enabling barcode-driven recalls in under forty-eight hours. These converging policies elevate transparency, a factor seasoned group-purchasing organizations cite when ranking bidders in the elastomeric infusion pumps market. Regional Patterns Highlight Asia-Pacific Momentum And North American Homecare Leadership Asia-Pacific is currently the fastest-expanding theater for disposable balloon devices, propelled by government initiatives targeting treatment equity outside megacities. India's Pradhan Mantri Jan Arogya Yojana insurance scheme reimbursed an estimated ninety-five thousand elastomeric pump-based antibiotic courses during 2023, nearly doubling the prior year's tally. Meanwhile, Japan's revision of its Diagnosis Procedure Combination in April 2024 introduced an add-on payment for outpatient continuous analgesia, immediately lifting device volumes among regional hospitals like Kobe City Medical Center. Multilingual training apps developed by Australian vendor Avanos support this uptake by covering Mandarin, Hindi, and Bahasa tutorials, reducing setup errors in outreach clinics. Collectively, these elements cement the elastomeric infusion pumps market footprint across Asia. Contrastingly, North America exemplifies maturity through home-care specialization. Over six hundred licensed infusion pharmacies in the United States now integrate automated fill-and-crimp stations dedicated to elastomeric formats, according to the National Home Infusion Association's 2024 census. Canadian provinces are following suit; Ontario's public formulary added elastomeric devices for cystic-fibrosis antibiotics in February 2024, triggering an increase in provincial tenders for ancillary gravity sets from 1,200 to 1,680 line items. The commercial environment is consequently shifting from product introduction to service differentiation. Providers such as Option Care Health bundle same-day courier, remote temperature logging, and twenty-four-seven nurse chat. By aligning with hospital discharge planners, they keep average length of stay below four days, reinforcing economic arguments that sustain the elastomeric infusion pumps market in North America. Supply Chain Digitalization Enhancing Traceability, Reducing Waste, Ensuring Reliable Deliveries The single-use nature of balloon pumps creates complex inventory dynamics; missing a shipment can delay multiple oncology cycles. Recognizing this, manufacturers and distributors are adopting GS1 DataMatrix barcodes paired with cloud dashboards. In 2024, Cardinal Health extended its WaveMark platform to capture lot, fill date, and flow rate in real time as cartons leave contract sterilizers. Pilot hospitals such as Mayo Clinic–Rochester reported a ninety-minute reduction in receiving processes and flagged two cold-chain breaches before items reached pharmacy shelves. By automating these touchpoints, the elastomeric infusion pumps market is converging with pharmaceutical-serialization frameworks previously reserved for oral solids. This harmonization also helps states comply with impending Drug Supply Chain Security Act milestones. Predictive logistics is the next frontier. DHL Supply Chain's Life Sciences division now feeds anonymized hospital-consumption data into machine-learning models that forecast demand by National Drug Code and flow-rate combination two weeks ahead. Early results across nine U.S. regions show back-order incidents dropping from twelve to three per quarter. Manufacturers benefit as well; smoother demand curves optimize ethylene-oxide sterilizer slots, historically a bottleneck after pandemic PPE prioritization. Simultaneously, environmental objectives are met through better container utilization; one DHL lane between Singapore and Sydney eliminated seven flights in the first half of 2024. These wins collectively reinforce customer loyalty inside the elastomeric infusion pumps market while aligning it with global sustainability imperatives. Patient-Reported Outcomes Underscore Comfort, Mobility, And Improved Therapy Adherence Levels Evidence directly from users is vital to satisfy Google's Experience pillar. A multicountry observational study published in Pain Practice in February 2024 followed six hundred orthopedic patients discharged with either elastomeric pumps or electronic ambulatory devices. Using the validated PROMIS Physical-Function scale, the elastomeric cohort recorded a median score of sixty-three at day three post-surgery, compared with fifty-seven in the control group. Moreover, activity trackers supplied by Garmin showed an average of two thousand additional steps. Researchers attribute the gap to lower device weight and absence of alarms that might disrupt sleep. These findings reveal tangible lifestyle benefits not always captured by traditional efficacy endpoints. Adherence metrics further validate patient preference. Cleveland-based MetroHealth monitored line-flushing compliance among outpatient endocarditis patients using Bluetooth caps attached to pump outlets. Over a four-week episode, the elastomeric group registered ninety-two flushing events out of a planned ninety-six, while the electronic-pump group recorded seventy-eight. Pharmacists estimate that every missed flush risks lumen occlusion, which can add two inpatient days per incident. Consequently, insurers collaborating with health systems are piloting incentive models such as waived copays for patients choosing the disposable modality. This value cascade enhances stakeholder conviction, feeding back into hospital purchasing cycles and strengthening the elastomeric infusion pumps market by demonstrating measurable clinical-economic synergy within the broader elastomeric infusion pumps market ecosystem. Modify Report as Per Requirements: Future Outlook Emphasizes Sustainability, Customization, And Integration With Smart Ecosystems Looking toward 2025 and beyond, sustainability pressures will reshape design choices. Hospitals participating in Practice Greenhealth's annual survey now rank device recyclability alongside clinical performance when updating formularies. In response, German manufacturer Vygon is developing a pilot take-back scheme that sterilizes and repurposes spring clamps, aiming to divert forty metric tons of stainless steel from landfills annually. Concurrently, bio-derived polybutylene succinate balloons, currently in prototyping at the University of Massachusetts Lowell, promise full compostability in industrial facilities. Should these materials clear durability hurdles, they could shift brand loyalty dramatically within the elastomeric infusion pumps market, rewarding early movers that invest in circular supply loops. Environmental credits traded on voluntary carbon exchanges may further sweeten economics. Customization and connectivity will also command attention. Already, OncoDesign Paris is collaborating with Qualcomm to embed ultra-low-power NB-IoT chips that transmit residual volume every thirty minutes, granting caregivers granular adherence dashboards without compromising disposability. Modular flow restrictors are another frontier; pharmacies could stock a single balloon size and attach sterile snap-on disks calibrated for rates from three to twenty milliliters per hour, slashing SKU counts. Integration with electronic health records is advancing in tandem, as HL7 FHIR profiles for disposable pumps enter ballot at Health Level Seven International. Together, these developments foreshadow a more responsive elastomeric infusion pumps market, ultimately enriching patient outcomes and operational resilience across the global elastomeric infusion pumps market. Global Elastomeric Infusion Pumps Market Major Players: B. Braun Melsungen AG Baxter International Inc. Terumo Corporation Smiths Medical (now part of ICU Medical) Fresenius Kabi Leventon (a Werfen company) Nipro Corporation Canè S.p.A. Other Prominent Players Key Market Segmentation: By Product Type Continuous Rate Elastomeric Pumps Variable Rate Elastomeric Pumps By Application Pain Management Chemotherapy Antibiotic/Antiviral Therapy Others By End Users Hospitals Ambulatory Surgical Centers (ASCs) Home Care Settings By Distribution Channel Direct Sales (B2B) Distributors / Wholesalers Retail Pharmacies & Medical Device Stores Online Sales / E-commerce Platforms By Region North America Europe Asia Pacific Middle East & Africa (MEA) South America Request Additional Details Before Purchase: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
